Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations.

Abnormal biology of alpha-synuclein (alpha-Syn) is directly implicated in the pathogenesis of Parkinson's disease and other alpha-synucleinopathies. Herein, we demonstrate that C-terminally truncated alpha-Syn (alpha-SynDeltaC), enriched in the pathological alpha-Syn aggregates, is normally generated from full-length alpha-Syn independent of alpha-Syn aggregation in brains and in cultured cells. The accumulation of alpha-SynDeltaC is enhanced in neuronal cells as compared with nonneuronal cells. Significantly, the expression of familial Parkinson's disease-linked mutant alpha-Syn is associated with the enhanced cellular accumulation of alpha-SynDeltaC. Moreover, substoichiometric amounts of alpha-SynDeltaC enhance the in vitro aggregation of the more abundant full-length alpha-Syn. Finally, cases of alpha-synucleinopathy exhibit increases in the total soluble alpha-Syn and a higher proportion of soluble alpha-SynDeltaC, a condition favoring the aggregation of alpha-Syn. Collectively, our results indicate that the biology behind the generation and accumulation of alpha-SynDeltaC is likely to have relevance for the initiation and the progression of alpha-Syn aggregation in vivo.

[1]  Nancy A. Jenkins,et al.  Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Goedert,et al.  Lewy body diseases and multiple system atrophy as α-synucleinopathies , 1998, Molecular Psychiatry.

[3]  Elan D. Louis,et al.  Merritt's Neurology , 2001 .

[4]  Y. Yang,et al.  Enhanced vulnerability to oxidative stress by α-synuclein mutations and C-terminal truncation , 2000, Neuroscience.

[5]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[6]  P J McLean,et al.  Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. , 2000, The Journal of biological chemistry.

[7]  D. Price,et al.  Axonal transport of human α‐synuclein slows with aging but is not affected by familial Parkinson's disease‐linked mutations , 2003, Journal of neurochemistry.

[8]  Jeon‐Han Park,et al.  Distinct Roles of the N-terminal-binding Domain and the C-terminal-solubilizing Domain of α-Synuclein, a Molecular Chaperone* , 2002, The Journal of Biological Chemistry.

[9]  J Q Trojanowski,et al.  Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[10]  E. Masliah,et al.  NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation. , 1997, Biochemical and biophysical research communications.

[11]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[12]  V. Uversky,et al.  Stabilization of Partially Folded Conformation during α-Synuclein Oligomerization in Both Purified and Cytosolic Preparations* , 2001, The Journal of Biological Chemistry.

[13]  R. Nussbaum,et al.  Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. , 2001, Human molecular genetics.

[14]  P. Lansbury,et al.  Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. , 2003, Biochemistry.

[15]  In-Kyung Kim,et al.  Rapid purification and analysis of α‐synuclein proteins: C‐terminal truncation promotes the conversion of α‐synuclein into a protease‐sensitive form in Escherichia coli , 2002 .

[16]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[17]  P. Thomas,et al.  Endoproteolytic Activity of the Proteasome , 2002, Science.

[18]  Sangram S. Sisodia,et al.  γ-Secretase, notch, Aβ and alzheimer's disease: Where do the presenilins fit in? , 2002, Nature Reviews Neuroscience.

[19]  J. Trojanowski,et al.  Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.

[20]  Chul-hak Yang,et al.  Structural and Functional Implications of C-Terminal Regions of α-Synuclein† , 2002 .

[21]  S. Lindquist,et al.  Yeast Cells Provide Insight into Alpha-Synuclein Biology and Pathobiology , 2003, Science.

[22]  L. Serpell,et al.  Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  John Q. Trojanowski,et al.  Distinct cleavage patterns of normal and pathologic forms of α‐synuclein by calpain I in vitro , 2003 .

[24]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[25]  S. Dunn,et al.  Effects of the modification of transfer buffer composition and the renaturation of proteins in gels on the recognition of proteins on Western blots by monoclonal antibodies. , 1986, Analytical biochemistry.

[26]  D. Dickson,et al.  Alpha-synuclein and the Lewy body disorders. , 2001, Current opinion in neurology.

[27]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[28]  Vladimir N. Uversky,et al.  Amino acid determinants of α‐synuclein aggregation: putting together pieces of the puzzle , 2002 .

[29]  He-Jin Lee,et al.  Clearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway , 2004, The Journal of Neuroscience.

[30]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[31]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[32]  H. Cai,et al.  BACE1 is the major β-secretase for generation of Aβ peptides by neurons , 2001, Nature Neuroscience.

[33]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[34]  John Q. Trojanowski,et al.  Induction of α-Synuclein Aggregation by Intracellular Nitrative Insult , 2001, The Journal of Neuroscience.

[35]  B. Giasson,et al.  Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. , 2000, The Journal of biological chemistry.

[36]  P. Axelsen,et al.  Role of α-Synuclein Carboxy-Terminus on Fibril Formation in Vitro† , 2003 .

[37]  J. Trojanowski,et al.  Parkinson's Disease and Related α‐Synucleinopathies Are Brain Amyloidoses , 2003, Annals of the New York Academy of Sciences.

[38]  Christopher A Ross,et al.  Polyglutamine Pathogenesis Emergence of Unifying Mechanisms for Huntington's Disease and Related Disorders , 2002, Neuron.

[39]  Akihiko Iwai,et al.  The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system , 1995, Neuron.

[40]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[41]  Colin L. Masters,et al.  α-Synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease β-amyloid plaque cores , 1999, Neuroscience Letters.